150 related articles for article (PubMed ID: 8465291)
1. [Optimal use of acid-inhibitors in acid-related diseases. Physiological and physiopathological considerations with implications on therapeutic choice].
Waldum HL
Tidsskr Nor Laegeforen; 1993 Feb; 113(4):465-9. PubMed ID: 8465291
[TBL] [Abstract][Full Text] [Related]
2. Review article: the use of gastric acid-inhibitory drugs--physiological and pathophysiological considerations.
Waldum HL; Brenna E; Kleveland PM; Sandvik AK; Syversen U
Aliment Pharmacol Ther; 1993 Dec; 7(6):589-96. PubMed ID: 7909240
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiology of reflux oesophagitis and peptic ulcer.
Gabryelewicz A
J Physiol Pharmacol; 1993 Sep; 44(3 Suppl 1):23-40. PubMed ID: 8260733
[TBL] [Abstract][Full Text] [Related]
4. Why is the high grade inhibition of gastric acid secretion afforded by proton pump inhibitors often required for healing of reflux esophagitis? An epithelial perspective.
Orlando RC
Am J Gastroenterol; 1996 Sep; 91(9):1692-6. PubMed ID: 8792683
[TBL] [Abstract][Full Text] [Related]
5. Controversies, dilemmas, and dialogues. Reduction of gastric acidity in the treatment of peptic ulcer disease: how low should we go?
Peterson WL; Harford WV
Am J Gastroenterol; 1991 Jun; 86(6):671-5. PubMed ID: 1674838
[No Abstract] [Full Text] [Related]
6. New molecular targets for treatment of peptic ulcer disease.
Lehmann F; Hildebrand P; Beglinger C
Drugs; 2003; 63(17):1785-97. PubMed ID: 12921485
[TBL] [Abstract][Full Text] [Related]
7. Omeprazole in the short-term treatment of reflux oesophagitis.
Jansen JB; Lamers CB
Digestion; 1989; 44 Suppl 1():40-6. PubMed ID: 2691310
[TBL] [Abstract][Full Text] [Related]
8. [Drug treatment of reflux esophagitis: effects of strong gastric acid inhibition].
Jansen JB; Lamers CB
Ned Tijdschr Geneeskd; 1989 Apr; 133(13):662-5. PubMed ID: 2566126
[No Abstract] [Full Text] [Related]
9. Clinical use of antacids.
Halter F
J Physiol Pharmacol; 1993 Sep; 44(3 Suppl 1):61-74. PubMed ID: 8260736
[TBL] [Abstract][Full Text] [Related]
10. Developments in the inhibition of gastric acid secretion.
Mössner J; Caca K
Eur J Clin Invest; 2005 Aug; 35(8):469-75. PubMed ID: 16101666
[TBL] [Abstract][Full Text] [Related]
11. The regulation of gastric acid secretion - clinical perspectives.
Waldum HL; Hauso Ø; Fossmark R
Acta Physiol (Oxf); 2014 Feb; 210(2):239-56. PubMed ID: 24279703
[TBL] [Abstract][Full Text] [Related]
12. Antacids. Indications and limitations.
Ching CK; Lam SK
Drugs; 1994 Feb; 47(2):305-17. PubMed ID: 7512903
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of peptic ulcer and reflux esophagitis with enzyme inhibitors].
Moriya S; Omura N; Kashiwagi H; Inagaki Y; Aoki T
Nihon Rinsho; 1991 Sep; 49(9):2115-9. PubMed ID: 1835742
[No Abstract] [Full Text] [Related]
14. The role of omeprazole in healing and prevention of reflux disease.
Klinkenberg-Knol EC
Hepatogastroenterology; 1992 Feb; 39 Suppl 1():27-30. PubMed ID: 1577392
[TBL] [Abstract][Full Text] [Related]
15. [Medical treatment of reflux peptic esophagitis: literature review].
Van Gossum M
Rev Med Brux; 1994; 15(1):20-4. PubMed ID: 7910701
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future.
Aihara T; Nakamura E; Amagase K; Tomita K; Fujishita T; Furutani K; Okabe S
Pharmacol Ther; 2003 Apr; 98(1):109-27. PubMed ID: 12667890
[TBL] [Abstract][Full Text] [Related]
17. Historical impact to drive research in peptic ulcer disease.
Banić M; Malfertheiner P; Babić Z; Ostojić R; Kujundzic M; Fatović-Ferenčić S; Plesko S; Petričušić L
Dig Dis; 2011; 29(5):444-53. PubMed ID: 22095008
[TBL] [Abstract][Full Text] [Related]
18. Control of gastric acid secretion. Histamine H2-receptor antagonists and H+K(+)-ATPase inhibitors.
Shamburek RD; Schubert ML
Gastroenterol Clin North Am; 1992 Sep; 21(3):527-50. PubMed ID: 1355465
[TBL] [Abstract][Full Text] [Related]
19. Current concepts in clinical therapeutics: peptic ulcer disease.
Siepler JK; Mahakian K; Trudeau WT
Clin Pharm; 1986 Feb; 5(2):128-42. PubMed ID: 2869852
[TBL] [Abstract][Full Text] [Related]
20. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
Clissold SP; Campoli-Richards DM
Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
